Inventory cancer immunotherapy "most expensive" transaction TOP10
Last September, the GEN website launched the "Top 15 Immuno-Oncology Collaborations" article, which summed up the "most expensive" 15 transactions in the Immuno-Oncology (IO) field, with a total value of about $30 billion. On April 3, the site updated this “list†and selected the top 10 in the IO field. Among them, Merck & Co. The $64 billion deal with Ablynx topped the list. The article said that the enthusiasm of biopharmaceutical companies to invest in cancer immunotherapy continues. Previously, the most "conservative" estimate of the cancer immunotherapy market was that the market would reach $34 billion (Global Data) in 2024; and according to more optimistic estimates by MarketsandMarkes, the market for cancer immunotherapy will reach about 2021. 120 billion US dollars. Behind these numbers is the expectation of sales growth. On the one hand, the earliest approved drugs are also increasing new indications. In 2016, the three best-selling cancer immunotherapy drugs have reached the level of “heavy drugsâ€, with annual sales exceeding US$1 billion: Opdivo’s cumulative sales last year reached US$3.774 billion, and Keytruda’s cumulative sales last year reached US$1,402 million and Yervoy’s cumulative sales last year reached $1,053 million. On the other hand, more and more new IO drugs are on the market. Not long ago, the approval of the Merck/Pfizer PD-L1 antibody ushered in the fourth largest member of the PD-1/PD-L1 antibody family. This time, the cumulative total value of TOP10 transactions listed by GEN is approximately $26.233 billion. details as follows: #10. Shire (Baxalta) and Symphogen Value: $1.5 billion Announcement date: January 4, 2016 Description of the cooperation: The two parties agreed to develop Symphonogen's early IO project portfolio and advance new treatments targeting six undisclosed checkpoints. The first project entered the clinic in 2017. #9. Shire (Baxalta) and Precision BioSciences Value: $1.7 billion, including $105 million in advance payments Announcement date: February 25, 2016 Co-op profile: The development of allogeneic CAR-T therapy based on Baxalta's Immuno-Oncology candidate and Precision's ARCUS gene editing platform. Both parties agreed to develop CAR-T therapies targeting up to six undisclosed targets. #8. Bristol-Myers Squibb (BMS) and Five Prime Therapeutics Value: $1.74 billion, including $350 million in advance payments Announcement date: October 15, 2015 Description of the cooperation: BMS agreed to cooperate in the development and commercialization of Five Prime's Colony Stimulating Factor 1 Receptor (CSF1R) antibody project. The leading candidate is the cancer/immunological compound cabilalizumab (FPA008). In the last 10 years, Five Prime launched an Ib clinical trial evaluating the combination of cabilalizumab+Opdivo. The two parties are evaluating the safety of this combination therapy strategy in a variety of advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, glioblastoma, renal cell carcinoma, and ovarian cancer. Tolerance and initial efficacy. Five Prime expects to complete the recruitment of the Phase Ib trial in the second half of this year. Fire Extinguisher Cylinder,Fire Co2 Cylinder,Co2 Fire Cylinder,Abc Fire Cylinder NINGBO TOMAN IMP. & EXP. CO., LTD , https://www.tdotmfiresolution.com